Page 5 - Wilmot Cancer Institute | UR Medicine

We will focus on what is essential to continuing to improve care—growing our research programs. Our talented
olid tumor cancers, and cancer control and survivorship.

BLOOD CANCERS

This program aims to improve treatment for patients
with a variety of blood cancers, from leukemia and
lymphoma to Hodgkin’s disease and myelodysplasia. Our
basic researchers follow two main paths: investigating
leukemia stem cells and drugs that can destroy them; and
understanding the tumor micro-environment, the interplay
between the body’s immune system, blood cancer, and
the blood vessels and tissues in the neighborhood of the
cancer. We’re also a national leader in clinical trials: our
researchers are designing more early-phase studies, offering
our patients access to the newest drugs long before they are
available to the general public.

CANCER CONTROL AND
SURVIVORSHIP

Thanks to significant research advances in the past decade,
there are more than 12 million cancer survivors—and
the numbers grow every day. Survivorship could reach
an estimated 18 million by 2020. The Wilmot Cancer
Institute has a rich history in cancer survivorship research
deepening our understanding of the risks of second
cancers after treatment, post-treatment brain fog, sleep
disorders, and nausea. We are now looking at specific ways
to reduce the side effects of chemotherapy and radiation,
and developing personalized models to predict who will
benefit most from various therapies.